The Claim
In mouse hepatocytes, the combination of efavirenz (30 μM) and isoniazid (1000 μM) synergistically inhibits mitochondrial complex I and II, leading to peroxynitrite stress, opening of the cyclosporine A-insensitive mitochondrial permeability transition pore, and necrotic cell death, while neither drug alone at these concentrations causes injury, indicating that co-exposure lowers the threshold for mitochondrial toxicity in liver cells.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When two specific drugs are taken together, they can damage liver cells in mice by disrupting their energy factories and causing cell death — but each drug alone, at the same dose, doesn't do anything harmful. This means the danger only shows up when both are present.
See the scientific wording
In mouse hepatocytes, the combination of efavirenz (30 μM) and isoniazid (1000 μM) synergistically inhibits mitochondrial complex I and II, leading to peroxynitrite stress, opening of the cyclosporine A-insensitive mitochondrial permeability transition pore, and necrotic cell death, while neither drug alone at these concentrations causes injury, suggesting that co-exposure lowers the threshold for mitochondrial toxicity in liver cells.
What the research says
1 studyWhen taken together, two drugs—efavirenz and isoniazid—hurt liver cells in mice by breaking down their energy factories, but neither drug hurts the cells alone. The study proves this dangerous combo works like a one-two punch on mitochondria.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.